title: Human equilibrative nucleoside transporter 1 and carcinoma of the ampulla of Vater: expression differences in tumour histotypes.
abstract: The human equilibrative nucleoside transporter 1 (hENT1) is the major means by which gemcitabine enters human cells; recent evidence exists that hENT1 is expressed in carcinoma of the ampulla of Vater and that it should be considered as a molecular prognostic marker for patients with resected ampullary cancer. Aim of the present study is to evaluate the variations of hENT1 expression in ampullary carcinomas and to correlate such variations with histological subtypes and clinicopathological parameters. Forty-one ampullary carcinomas were histologically classified into intestinal, pancreaticobiliary and unusual types. hENT1 and Ki67 expression were evaluated by immunohistochemistry, and apoptotic cells were identified by the terminal deoxynucleotidyl transferase mediated deoxyuridine triphosphate biotin nick end labelling (TUNEL) method. hENT1 overexpression was detected in 63.4% ampullary carcinomas. A significant difference in terms of hENT1 and Ki67 expression was found between intestinal vs. pancreaticobiliary types (P=0.03 and P=0.009 respectively). Moreover, a significant statistical positive correlation was found between apoptotic and proliferative Index (P=0.036), while no significant correlation was found between hENT1 and apoptosis. Our results on hENT1 expression suggest that classification of ampullary carcinoma by morphological subtypes may represent an additional tool in prospective clinical trials aimed at examining treatment efficacy; in addition, data obtained from Ki67 and TUNEL suggest a key role of hENT1 in tumour growth of ampullary carcinoma.
authors.affiliation: Department of Anatomical Pathology, Campus Bio-Medico University, via Alvaro del Portillo 200, Rome, Italy. g.perrone@unicampus.it
authors.forename: G
authors.initials: G
authors.lastname: Perrone
authors.forename: S
authors.initials: S
authors.lastname: Morini
authors.forename: D
authors.initials: D
authors.lastname: Santini
authors.forename: C
authors.initials: C
authors.lastname: Rabitti
authors.forename: B
authors.initials: B
authors.lastname: Vincenzi
authors.forename: R
authors.initials: R
authors.lastname: Alloni
authors.forename: A
authors.initials: A
authors.lastname: Antinori
authors.forename: P
authors.initials: P
authors.lastname: Magistrelli
authors.forename: R
authors.initials: R
authors.lastname: Lai
authors.forename: C
authors.initials: C
authors.lastname: Cass
authors.forename: J R
authors.initials: JR
authors.lastname: Mackey
authors.forename: R
authors.initials: R
authors.lastname: Coppola
authors.forename: G
authors.initials: G
authors.lastname: Tonini
authors.forename: A
authors.initials: A
authors.lastname: Onetti Muda
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology*; D000328:Adult; D000368:Aged; D014670:Ampulla of Vater / Q000378:metabolism / Q000473:pathology*; D017209:Apoptosis; D002277:Carcinoma / Q000378:metabolism* / Q000473:pathology; D033721:Equilibrative Nucleoside Transporter 1 / Q000378:metabolism*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007414:Intestinal Neoplasms / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000378:metabolism* / Q000473:pathology
chemical_list: D033721:Equilibrative Nucleoside Transporter 1